Tolvaptan treatment in an adult Fontan patient with protein-losing enteropathy: a serial Na-MRI investigation
Background: Protein-losing enteropathy (PLE) is a severe complication of the univentricular Fontan circulation and associated with disturbances in salt and water homeostasis. Fontan patients with PLE have a poor prognosis, with increased morbidity and mortality. Due to limited therapeutic strategies...
Main Authors: | Julia Moosmann, Okan Toka, Peter Linz, Anke Dahlmann, Armin M. Nagel, Mario Schiffer, Michael Uder, Robert Cesnjevar, Sven Dittrich, Christoph Kopp |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-04-01
|
Series: | Therapeutic Advances in Chronic Disease |
Online Access: | https://doi.org/10.1177/20406223211004005 |
Similar Items
-
Enteropatia perdedora de proteínas após cirurgia de Fontan Protein-losing enteropathy after the Fontan operation
by: Fernando Tadeu Vasconcelos Amaral, et al.
Published: (2006-10-01) -
First experience with Tolvaptan for the treatment of neonates and infants with capillary leak syndrome after cardiac surgery
by: Anne Kerling, et al.
Published: (2019-02-01) -
Protein-losing enteropathy
by: A I Parfenov, et al.
Published: (2017-02-01) -
Protein-Losing Enteropathy in Primary Lymphangiectasia
by: Bernard Crutzen, et al.
Published: (2020-06-01) -
Protein-Losing Enteropathy in Ulcerative Colitis
by: Ryan Ungaro, et al.
Published: (2012-04-01)